히스톤 탈아세틸화효소 억제제 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Histone Deacetylase Inhibitors Market was valued at USD 1.3 billion in 2024 and is projected to expand at a CAGR of 7.7% between 2025 and 2034. Histone deacetylase (HDAC) inhibitors play a crucial role in modifying gene expression by removing acetyl groups from histones, thereby influencing cellular mechanisms linked to various diseases. The market is witnessing steady growth driven by the rising incidence of cancer, neurological disorders, and autoimmune diseases, which continue to increase the demand for effective HDAC inhibitors. Additionally, continuous advancements in drug development, coupled with regulatory approvals and targeted therapy innovations, further accelerate market expansion. Increasing research into HDAC inhibitors' role in overcoming chemotherapy resistance and enhancing treatment efficacy is also fueling industry growth. Moreover, the growing investment in biotechnology and pharmaceutical research, alongside collaborations between key industry players, is expected to enhance the commercialization of new HDAC inhibitor therapies.

HDAC inhibitors are widely utilized in oncology, neurology, cardiovascular diseases, and autoimmune conditions. Their application is particularly crucial for patients in advanced disease stages, as they are often administered prior to systemic chemotherapy to optimize treatment outcomes. Given the rising prevalence of multiple myeloma, T-cell lymphoma, and neurodegenerative diseases, the need for innovative HDAC inhibitors continues to grow. Furthermore, an increasing number of clinical trials focused on expanding therapeutic applications for HDAC inhibitors beyond cancer treatment is expected to contribute to market growth over the forecast period.

The histone deacetylase inhibitors market is categorized based on distribution channels, with key segments including hospital pharmacies, retail pharmacies, and e-commerce. In 2024, the hospital pharmacies segment accounted for USD 830.7 million in revenue. This dominance is largely attributed to the need for continuous patient monitoring and stringent dosage regulation associated with approved HDAC inhibitors. Due to the potential severity of side effects and toxicity risks, these inhibitors are often administered in hospital settings, which drives demand within this distribution channel. Hospitals equipped with advanced oncology and infusion centers remain the preferred sites for HDAC inhibitor treatments, reinforcing the segment's leading position in the market.

The hydroxamic acid derivatives segment is expected to generate substantial revenue from 2025 to 2034. Recognized as some of the most potent HDAC inhibitors, hydroxamic acid derivatives are extensively used in cancer therapies. Their ability to suppress tumor growth and overcome chemotherapy resistance makes them essential in oncology. As the prevalence of cancers such as multiple myeloma and T-cell lymphoma continues to rise, the demand for these inhibitors is projected to surge. Advancements in research and clinical studies further strengthen their role in cancer treatment, ensuring sustained market growth.

The U.S. Histone Deacetylase Inhibitors Market is poised to experience significant revenue growth between 2025 and 2034. Regulatory agencies such as the FDA actively approve new HDAC inhibitors, particularly those designated as orphan drugs, fast-tracked, or given priority review, which helps stimulate market expansion. Additionally, the increasing prevalence of Alzheimer's disease in the U.S. has heightened interest in the neuroprotective effects of HDAC inhibitors, further driving market demand. With a strong presence of leading biotechnology and pharmaceutical companies in the country, innovation in HDAC inhibitor therapies continues to advance, contributing to overall market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising cancer incidence
    • 3.2.1.2 Expanding applications beyond oncology
    • 3.2.1.3 Growing R&D investments and clinical trials
    • 3.2.1.4 Regulatory approvals and orphan drug designations
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Toxicity and side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Gap analysis
• 3.6 Patent analysis
• 3.7 Pipeline analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Hydroxamic acid derivatives
• 5.3 Cyclic peptides
• 5.4 Benzamides

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oncology
• 6.3 Neurology
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Bristol-Myers Squibb Company
• 9.2 Chipscreen Bioscience
• 9.3 ITF Therapeutics
• 9.4 Merck & Co.
• 9.5 Novartis
• 9.6 Spectrum Pharmaceuticals
• 9.7 Taizhou EOC Pharma